DOI: 10.36347/sasjs.2020.v06i04.006

Pages: 184-191

Bladder carcinoma is diagnosed or treated worldwide in 2.7 million people each year and, in the majority of cases, urothelial tumors appear after 60 years. Over a period of 4 years from 2016 to 2019, 63 patients benefited from BCUV adjuvant therapy at RTUV. The average age of the patients is 58 years. The sex ratio is 5.7 predominantly male Smoking was found in 66% of patients. The predominant reason for consultation is hematuria in 87.2%. Ultrasound of the urinary tract showed a bladder bladder tumor in 49 patients, with bladder thickening in 10 patients and bladder bladder disease in 4 patients. During cystoscopy with diagnostic RTUV, the tumor was unifocal in 38.2% and multifocal in 61.7%. In the pathology study, it was urothelial carcinoma in 62 patients, only 1 patient had carcinoma in situ and 6 patients had the same lesions at the same time. All patients benefited from a complete RTUV followed by BCG therapy. The most used product is BCG culture at a dose of 120 mg per instillation. The protocol used is one instillation / week for 6 weeks followed by another series of 3 weekly instillations after a rest of 6 weeks, then maintenance schedule on the basis of 3 weekly instillations at 3 months, 6 months, then every 6 months for 3 years. 4 patients experienced side effects from BCG therapy. RTUV with surveillance was performed on his patients. Cystoscopy and urine cytology are the monitoring methods used. The control cystoscopy showed a recurrence in 10 patients. Progression of the tumor was found in 7 patients. The therapeutic alternative is discussed case by case.